董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aaron Fletcher | 男 | Chairman of the Board | 44 | 6.85万美元 | 未持股 | 2023-10-04 |
| Stephen C. Rocamboli | 男 | Independent Director | 52 | 7.35万美元 | 未持股 | 2023-10-04 |
| Harlan Weisman | -- | President, Chief Executive Officer and Director | 71 | 7.90万美元 | 未持股 | 2023-10-04 |
| Brandi Roberts | 女 | Independent Director | 50 | 53.56万美元 | 未持股 | 2023-10-04 |
| Robert S. Mills | 男 | Independent Director | 70 | 16.85万美元 | 未持股 | 2023-10-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kirk Coleman | 男 | Chief Financial Officer | 51 | 38.22万美元 | 未持股 | 2023-10-04 |
| Harlan Weisman | -- | President, Chief Executive Officer and Director | 71 | 7.90万美元 | 未持股 | 2023-10-04 |
| Christopher Cano | 男 | Chief Operating Officer and Vice President of Business Development | 53 | 35.36万美元 | 未持股 | 2023-10-04 |
| Zamaneh Mikhak | 女 | Chief Medical Officer | 58 | 未披露 | 未持股 | 2023-10-04 |
董事简历
中英对照 | 中文 | 英文- Aaron Fletcher
-
Aaron Fletcher自2018年1月起担任董事会成员，自2018年12月起担任董事会主席。自2012年以来，Fletcher博士一直担任BIOS Research的创始人兼总裁，该公司是一家金融服务公司，为机构公司和大型家族办公室量身定制梦百合行业的公共股票研究。自2014年以来，Fletcher博士还担任BIOS Partners，LP的管理合伙人，该公司是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。弗莱彻博士还担任LTI公司、Cue Biopharma公司（纳斯达克市场代码:CUE）、SWK Holdings Corporation（纳斯达克市场代码:SWKH）、Actuate Therapeutics公司、Abilitech Medical公司和CogRx Therapeutics公司的董事。Fletcher博士拥有科罗拉多州立大学（Colorado State University）生物化学博士学位，并担任达拉斯浸信会大学（Dallas Baptist University）客座教授。Fletcher博士在生物技术/梦百合股票行业担任了十多年的独立顾问。
Aaron Fletcher has served as a member of our Board since January 2018 and has served as the Chairman of the Board since December 2018. Since 2012 Dr. Fletcher has served as founder and President of Bios Research, a financial services firm that provides public equity research in the healthcare industry tailored to institutional firms and large family offices. Since 2014 Dr. Fletcher has also served as Managing Partner of Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. Dr. Fletcher also serves as a director of LTI, Cue Biopharma, Inc Nasdaq: CUE, SWK Holdings Corporation (Nasdaq: SWKH), Actuate Therapeutics, AbiliTech Medical, and CogRx Therapeutics. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University and serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over ten years. - Aaron Fletcher自2018年1月起担任董事会成员，自2018年12月起担任董事会主席。自2012年以来，Fletcher博士一直担任BIOS Research的创始人兼总裁，该公司是一家金融服务公司，为机构公司和大型家族办公室量身定制梦百合行业的公共股票研究。自2014年以来，Fletcher博士还担任BIOS Partners，LP的管理合伙人，该公司是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。弗莱彻博士还担任LTI公司、Cue Biopharma公司（纳斯达克市场代码:CUE）、SWK Holdings Corporation（纳斯达克市场代码:SWKH）、Actuate Therapeutics公司、Abilitech Medical公司和CogRx Therapeutics公司的董事。Fletcher博士拥有科罗拉多州立大学（Colorado State University）生物化学博士学位，并担任达拉斯浸信会大学（Dallas Baptist University）客座教授。Fletcher博士在生物技术/梦百合股票行业担任了十多年的独立顾问。
- Aaron Fletcher has served as a member of our Board since January 2018 and has served as the Chairman of the Board since December 2018. Since 2012 Dr. Fletcher has served as founder and President of Bios Research, a financial services firm that provides public equity research in the healthcare industry tailored to institutional firms and large family offices. Since 2014 Dr. Fletcher has also served as Managing Partner of Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. Dr. Fletcher also serves as a director of LTI, Cue Biopharma, Inc Nasdaq: CUE, SWK Holdings Corporation (Nasdaq: SWKH), Actuate Therapeutics, AbiliTech Medical, and CogRx Therapeutics. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University and serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over ten years.
- Stephen C. Rocamboli
-
StephenC.Rocamboli自2018年12月起担任董事会成员。Rocamboli先生于2015年4月至2020年5月担任Advantagene，Inc.，D/B/A Candel Therapeutics（一家位于马萨诸塞州尼达姆的私人免疫肿瘤学公司）的首席商务官，总法律顾问兼公司秘书。2010年至2015年4月，Rocamboli先生担任Integrin Partners，LLC的普通合伙人，这是一家为生命科学公司、投资者和企业家提供企业发展和战略交易咨询and General Counsel服务的咨询公司。从2010年到2012年，Rocamboli先生还担任北京国际集团（Beijing International Group）的合伙人，该公司是Integrin Partners的国际子公司。2014年至2015年，Rocamboli先生还担任Wyrick Robbins Yates&Ponton，LLP的特别法律顾问，专注于生命科学交易。在2008年至2018年期间，Rocamboli先生是梨树制药的联合创始人并担任总裁，一家处于发展阶段的制药公司，专注于创新药物的开发和商业化，以满足老年妇女和乳腺癌妇女独特的未满足需求，直到将其出售给DAR&233；Bioscience，Inc.。在加入Pear Tree之前，Rocamboli先生曾于2004年至2007年担任Paramount BioCapital及其附属公司的高级常务董事and General Counsel，并于1999年至2004年担任Paramount的副总法律顾问。任职Paramount公司期间，他也曾担任Orion Biomedical Fund的合伙人。Rocamboli先生曾担任多家公共和私人生命科学公司的董事会成员，包括2015年出售给Shire Pharmaceuticals的Foresight Biotherapeutics，目前担任纽约两家私人持有的生命科学公司的董事会成员。Rocamboli先生在纽约州立大学奥尔巴尼分校（State University of New York at Albany）获得学士学位，并在福特汉姆大学法学院（Fordham University School of Law）获得法学博士学位。
Stephen C. Rocamboli,has served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Mr. Rocamboli has served as the founder, Chief Executive Officer and Chairman of the Board of Perla Therapeutics, Inc. since June 2020. Prior to founding Perla Therapeutics, Mr. Rocamboli served as Chief Business Officer, General Counsel and Corporate Secretary of Candel Therapeutics, an immuno-oncology company based in Needham, Massachusetts, between April 2015 and May 2020 (NASDAQ: CADL). Between 2010 and 2015, Mr. Rocamboli served as general partner of Integrin Partners, LLC, a consulting firm providing corporate development, strategic transaction advisory and general counsel services to life science companies, investors and entrepreneurs. Between 2010 and 2012, Mr. Rocamboli also served as partner of Beijing International Group, an international affiliate of Integrin Partners. Between 2014 and 2015, Mr. Rocamboli also served as Special Counsel to Wyrick Robbins Yates & Ponton, LLP, focusing on life sciences transactions. Between 2008 and 2018, Mr. Rocamboli was a co-founder and served as President of Pear Tree Pharmaceuticals, until its sale to Daré Bioscience, Inc. (NASDAQ: DARE). Prior to joining Pear Tree, Mr. Rocamboli spent nearly a decade as a senior executive of a New York, NY based private FINRA/SEC member investment bank, venture capital firm, and affiliated hedge funds, focused exclusively on biotechnology and specialty pharmaceuticals. Mr. Rocamboli held positions of increasing responsibility, with the last five years as Senior Managing Director and General Counsel of all business units. Mr. Rocamboli has served as a member of the board of directors of several public and private life sciences companies, including Foresight Biotherapeutics (sold to Shire Pharmaceuticals in 2015) and currently serves as a member of the board of Esperion, Inc., Ann Arbor, MI (NASDAQ: ESPR). Mr. Rocamboli received his B.A. from The State University of New York at Albany and his J.D. from Fordham University School of Law. - StephenC.Rocamboli自2018年12月起担任董事会成员。Rocamboli先生于2015年4月至2020年5月担任Advantagene，Inc.，D/B/A Candel Therapeutics（一家位于马萨诸塞州尼达姆的私人免疫肿瘤学公司）的首席商务官，总法律顾问兼公司秘书。2010年至2015年4月，Rocamboli先生担任Integrin Partners，LLC的普通合伙人，这是一家为生命科学公司、投资者和企业家提供企业发展和战略交易咨询and General Counsel服务的咨询公司。从2010年到2012年，Rocamboli先生还担任北京国际集团（Beijing International Group）的合伙人，该公司是Integrin Partners的国际子公司。2014年至2015年，Rocamboli先生还担任Wyrick Robbins Yates&Ponton，LLP的特别法律顾问，专注于生命科学交易。在2008年至2018年期间，Rocamboli先生是梨树制药的联合创始人并担任总裁，一家处于发展阶段的制药公司，专注于创新药物的开发和商业化，以满足老年妇女和乳腺癌妇女独特的未满足需求，直到将其出售给DAR&233；Bioscience，Inc.。在加入Pear Tree之前，Rocamboli先生曾于2004年至2007年担任Paramount BioCapital及其附属公司的高级常务董事and General Counsel，并于1999年至2004年担任Paramount的副总法律顾问。任职Paramount公司期间，他也曾担任Orion Biomedical Fund的合伙人。Rocamboli先生曾担任多家公共和私人生命科学公司的董事会成员，包括2015年出售给Shire Pharmaceuticals的Foresight Biotherapeutics，目前担任纽约两家私人持有的生命科学公司的董事会成员。Rocamboli先生在纽约州立大学奥尔巴尼分校（State University of New York at Albany）获得学士学位，并在福特汉姆大学法学院（Fordham University School of Law）获得法学博士学位。
- Stephen C. Rocamboli,has served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Mr. Rocamboli has served as the founder, Chief Executive Officer and Chairman of the Board of Perla Therapeutics, Inc. since June 2020. Prior to founding Perla Therapeutics, Mr. Rocamboli served as Chief Business Officer, General Counsel and Corporate Secretary of Candel Therapeutics, an immuno-oncology company based in Needham, Massachusetts, between April 2015 and May 2020 (NASDAQ: CADL). Between 2010 and 2015, Mr. Rocamboli served as general partner of Integrin Partners, LLC, a consulting firm providing corporate development, strategic transaction advisory and general counsel services to life science companies, investors and entrepreneurs. Between 2010 and 2012, Mr. Rocamboli also served as partner of Beijing International Group, an international affiliate of Integrin Partners. Between 2014 and 2015, Mr. Rocamboli also served as Special Counsel to Wyrick Robbins Yates & Ponton, LLP, focusing on life sciences transactions. Between 2008 and 2018, Mr. Rocamboli was a co-founder and served as President of Pear Tree Pharmaceuticals, until its sale to Daré Bioscience, Inc. (NASDAQ: DARE). Prior to joining Pear Tree, Mr. Rocamboli spent nearly a decade as a senior executive of a New York, NY based private FINRA/SEC member investment bank, venture capital firm, and affiliated hedge funds, focused exclusively on biotechnology and specialty pharmaceuticals. Mr. Rocamboli held positions of increasing responsibility, with the last five years as Senior Managing Director and General Counsel of all business units. Mr. Rocamboli has served as a member of the board of directors of several public and private life sciences companies, including Foresight Biotherapeutics (sold to Shire Pharmaceuticals in 2015) and currently serves as a member of the board of Esperion, Inc., Ann Arbor, MI (NASDAQ: ESPR). Mr. Rocamboli received his B.A. from The State University of New York at Albany and his J.D. from Fordham University School of Law.
- Harlan Weisman
-
Harlan Weisman自2018年12月起担任董事会成员。自2020年1月以来，Weisman博士一直担任Flame Biosciences，Inc.（一家临床阶段公司，专注于炎症驱动的癌症和其他炎症条件的转化疗法的研究，开发和商业化）的董事长兼首席执行官。自2012年以来，Weisman博士还一直担任AND-ONE Consulting，LLC的董事总经理，该公司从事为医疗产品公司，投资公司以及政府和非政府梦百合组织提供建议的业务，以制定和实施推动梦百合产品和服务创新的战略。自2014年以来，Weisman博士还担任3DBio Therapeutics的董事会执行主席，该公司使用3D生物打印技术开发完全整合到身体中的整个组织植入物。从2016年2月至2019年，Weisman博士担任Mycrobiomics的联合创始人兼首席科学官，该公司开发咨询和教育材料，以帮助消费者了解微生物组并改善其健康和福祉。2012年12月至2013年12月，Weisman博士担任Coronado Biosciences（一家生物制药公司，为自身免疫性疾病和癌症开发新型免疫疗法）的董事长兼首席执行官。2012年至2019年，Weisman博士曾担任Controlrad，Inc（一家医疗设备公司，开发技术以减少透视过程中的辐射暴露）的董事会成员。Weisman博士还担任Caelum Biosciences，Inc.的董事会成员。自2012年以来，魏斯曼博士还一直担任CRG的高级顾问，CRG是一家投资管理公司，对梦百合公司进行结构性债务和股权投资。自2016年以来，Weisman博士一直担任以色列生物技术基金（Israel Biotech Fund）的风险顾问，该基金投资和开发位于以色列的临床阶段生物技术公司。从2010年到2016年，Weisman博士担任以患者为中心的结果研究所的董事会成员，该研究所由美国国会成立，是2010年《患者保护和负担得起的医疗法案》的一部分。Weisman博士从2006年到2012年担任强生公司医疗设备和诊断集团首席科技官，并担任强生全球研发理事会主席。Weisman从2004年到2006年担任J&J Pharmaceutical Research&Development公司集团主席。
Harlan Weisman,has served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer since December 4, 2022. Dr. Weisman has also served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Since 2012, Dr. Weisman has also been Managing Director of And-One Consulting, LLC, which is engaged in the business of advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Since 2014, Dr. Weisman has also served as Executive Chairman of the Board of 3DBio Therapeutics, a company Tff Pharmaceuticals, Inc. ing 3D bioprinting technology to develop whole tissue implants that fully integrate into body. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer, from January 2020 to January 2022. From February 2016 through 2019, Dr. Weisman served as co-founder and Chief Scientific Officer for Mycrobiomics, a company developing counseling and educational material to help consumers to understand the microbiome and improve their health and well-being. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Between 2012 and 2019, Dr. Weisman served on the Board of Directors of ControlRad, Inc, a medical device company developing technology to reduce radiation exposure during fluoroscopic procedures. Dr. Weisman also served on the Board of Directors of Caelum Biosciences, Inc from 2019 until its acquisition by AstraZeneca in 2021. Since 2012, Dr. Weisman has also been an Operating Partner at CRG, an investment management firm making structured debt and equity investments in healthcare companies. Since 2016, Dr. Weisman has been a venture advisor to the Israel Biotech Fund, which invests and develops clinical-stage biotechnology companies based in Israel. From 2010 to 2016, Dr. Weisman served on the Board of Governors of the Patient Centered Outcomes Research Institute, established by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. Dr. Weisman was the Chief Science and Technology Officer of the Johnson & Johnson Medical Devices and Diagnostics Group from 2006 to 2012 and served as Chairman of the J&J Worldwide R&D Council. Dr. Weisman was Company Group Chairman of J&J Pharmaceutical Research & Development from 2004 to 2006. - Harlan Weisman自2018年12月起担任董事会成员。自2020年1月以来，Weisman博士一直担任Flame Biosciences，Inc.（一家临床阶段公司，专注于炎症驱动的癌症和其他炎症条件的转化疗法的研究，开发和商业化）的董事长兼首席执行官。自2012年以来，Weisman博士还一直担任AND-ONE Consulting，LLC的董事总经理，该公司从事为医疗产品公司，投资公司以及政府和非政府梦百合组织提供建议的业务，以制定和实施推动梦百合产品和服务创新的战略。自2014年以来，Weisman博士还担任3DBio Therapeutics的董事会执行主席，该公司使用3D生物打印技术开发完全整合到身体中的整个组织植入物。从2016年2月至2019年，Weisman博士担任Mycrobiomics的联合创始人兼首席科学官，该公司开发咨询和教育材料，以帮助消费者了解微生物组并改善其健康和福祉。2012年12月至2013年12月，Weisman博士担任Coronado Biosciences（一家生物制药公司，为自身免疫性疾病和癌症开发新型免疫疗法）的董事长兼首席执行官。2012年至2019年，Weisman博士曾担任Controlrad，Inc（一家医疗设备公司，开发技术以减少透视过程中的辐射暴露）的董事会成员。Weisman博士还担任Caelum Biosciences，Inc.的董事会成员。自2012年以来，魏斯曼博士还一直担任CRG的高级顾问，CRG是一家投资管理公司，对梦百合公司进行结构性债务和股权投资。自2016年以来，Weisman博士一直担任以色列生物技术基金（Israel Biotech Fund）的风险顾问，该基金投资和开发位于以色列的临床阶段生物技术公司。从2010年到2016年，Weisman博士担任以患者为中心的结果研究所的董事会成员，该研究所由美国国会成立，是2010年《患者保护和负担得起的医疗法案》的一部分。Weisman博士从2006年到2012年担任强生公司医疗设备和诊断集团首席科技官，并担任强生全球研发理事会主席。Weisman从2004年到2006年担任J&J Pharmaceutical Research&Development公司集团主席。
- Harlan Weisman,has served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer since December 4, 2022. Dr. Weisman has also served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Since 2012, Dr. Weisman has also been Managing Director of And-One Consulting, LLC, which is engaged in the business of advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Since 2014, Dr. Weisman has also served as Executive Chairman of the Board of 3DBio Therapeutics, a company Tff Pharmaceuticals, Inc. ing 3D bioprinting technology to develop whole tissue implants that fully integrate into body. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer, from January 2020 to January 2022. From February 2016 through 2019, Dr. Weisman served as co-founder and Chief Scientific Officer for Mycrobiomics, a company developing counseling and educational material to help consumers to understand the microbiome and improve their health and well-being. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Between 2012 and 2019, Dr. Weisman served on the Board of Directors of ControlRad, Inc, a medical device company developing technology to reduce radiation exposure during fluoroscopic procedures. Dr. Weisman also served on the Board of Directors of Caelum Biosciences, Inc from 2019 until its acquisition by AstraZeneca in 2021. Since 2012, Dr. Weisman has also been an Operating Partner at CRG, an investment management firm making structured debt and equity investments in healthcare companies. Since 2016, Dr. Weisman has been a venture advisor to the Israel Biotech Fund, which invests and develops clinical-stage biotechnology companies based in Israel. From 2010 to 2016, Dr. Weisman served on the Board of Governors of the Patient Centered Outcomes Research Institute, established by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. Dr. Weisman was the Chief Science and Technology Officer of the Johnson & Johnson Medical Devices and Diagnostics Group from 2006 to 2012 and served as Chairman of the J&J Worldwide R&D Council. Dr. Weisman was Company Group Chairman of J&J Pharmaceutical Research & Development from 2004 to 2006.
- Brandi Roberts
-
Brandi Roberts，自2022年3月25日起担任TFF Pharmaceuticals, Inc.董事会成员。罗伯茨女士拥有超过25年的公共会计和金融经验，其中22年在上市的制药、医疗技术和生命科学公司工作。罗伯茨女士自2021年1月起担任上市的临床阶段生物制药公司Longboard Pharmaceuticals, Inc.的首席财务官。此前，罗伯茨女士于2019年1月至2021年1月担任上市的临床阶段生物技术公司Lineage Cell Therapeutics, Inc.的首席财务官。罗伯茨女士于2017年8月至2019年1月担任医疗设备公司REVA Medical，Inc.的首席财务官。随后，Reva于2020年1月14日提交了一份预先包装好的自愿破产申请，并于2020年2月26日从美国的破产保护中脱身。罗伯茨女士曾于2013年1月至2017年4月担任上市生物制药公司Mast Therapeutics，Inc.的首席财务官，并于2011年3月至2013年1月担任其财务高级副总裁。此前，她曾在Alphatec Spine，Inc.、Artes Medical，Inc.、Stratagene Corporation和辉瑞公司担任高级职务。罗伯茨女士目前担任生物科学财务官员协会南加州分会主席，自2019年11月起担任Temple Therapeutics BV董事会成员。罗伯茨女士是加利福尼亚州的注册会计师，在亚利桑那大学获得工商管理学士学位，在圣迭戈大学获得工商管理硕士学位。
Brandi Roberts,has served as a member of Tff Pharmaceuticals, Inc. Board since March 25, 2022. Ms. Roberts has more than 25 years of public accounting and finance experience, including 22 years at publicly traded pharmaceutical, medical technology, and life science companies. Ms. Roberts has served as the Chief Financial Officer of Longboard Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company, since January 2021. Previously, Ms. Roberts served as Chief Financial Officer of Lineage Cell Therapeutics, Inc., a publicly traded clinical-stage biotechnology company, from January 2019 to January 2021. Ms. Roberts served as Chief Financial Officer of REVA Medical, Inc., a medical device company, from August 2017 to January 2019. Subsequently, Reva filed a prepackaged voluntary Chapter 11 bankruptcy petition on January 14, 2020 and emerged from bankruptcy protection in United States effective February 26, 2020. Ms. Roberts previously served as Chief Financial Officer of Mast Therapeutics, Inc., a publicly traded biopharmaceutical company, from January 2013 to April 2017, and as its Senior Vice President, Finance, from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers and has served on the Board of Temple Therapeutics BV since November 2019. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego. - Brandi Roberts，自2022年3月25日起担任TFF Pharmaceuticals, Inc.董事会成员。罗伯茨女士拥有超过25年的公共会计和金融经验，其中22年在上市的制药、医疗技术和生命科学公司工作。罗伯茨女士自2021年1月起担任上市的临床阶段生物制药公司Longboard Pharmaceuticals, Inc.的首席财务官。此前，罗伯茨女士于2019年1月至2021年1月担任上市的临床阶段生物技术公司Lineage Cell Therapeutics, Inc.的首席财务官。罗伯茨女士于2017年8月至2019年1月担任医疗设备公司REVA Medical，Inc.的首席财务官。随后，Reva于2020年1月14日提交了一份预先包装好的自愿破产申请，并于2020年2月26日从美国的破产保护中脱身。罗伯茨女士曾于2013年1月至2017年4月担任上市生物制药公司Mast Therapeutics，Inc.的首席财务官，并于2011年3月至2013年1月担任其财务高级副总裁。此前，她曾在Alphatec Spine，Inc.、Artes Medical，Inc.、Stratagene Corporation和辉瑞公司担任高级职务。罗伯茨女士目前担任生物科学财务官员协会南加州分会主席，自2019年11月起担任Temple Therapeutics BV董事会成员。罗伯茨女士是加利福尼亚州的注册会计师，在亚利桑那大学获得工商管理学士学位，在圣迭戈大学获得工商管理硕士学位。
- Brandi Roberts,has served as a member of Tff Pharmaceuticals, Inc. Board since March 25, 2022. Ms. Roberts has more than 25 years of public accounting and finance experience, including 22 years at publicly traded pharmaceutical, medical technology, and life science companies. Ms. Roberts has served as the Chief Financial Officer of Longboard Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company, since January 2021. Previously, Ms. Roberts served as Chief Financial Officer of Lineage Cell Therapeutics, Inc., a publicly traded clinical-stage biotechnology company, from January 2019 to January 2021. Ms. Roberts served as Chief Financial Officer of REVA Medical, Inc., a medical device company, from August 2017 to January 2019. Subsequently, Reva filed a prepackaged voluntary Chapter 11 bankruptcy petition on January 14, 2020 and emerged from bankruptcy protection in United States effective February 26, 2020. Ms. Roberts previously served as Chief Financial Officer of Mast Therapeutics, Inc., a publicly traded biopharmaceutical company, from January 2013 to April 2017, and as its Senior Vice President, Finance, from March 2011 to January 2013. Previously, she held senior positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts currently serves as Chair of the Southern California Chapter of the Association of Bioscience Financial Officers and has served on the Board of Temple Therapeutics BV since November 2019. Ms. Roberts is a certified public accountant with the State of California and received her B.S. degree in business administration from the University of Arizona and her M.B.A. from the University of San Diego.
- Robert S. Mills
-
Robert S. Mills曾担任总裁，自2006年1月起担任公司董事会成员。他于2006年3月至2009年12月担任首席执行官。Mills先生于2001年5月加入 Columbia，担任公司运营的高级副总裁，并于2003年9月被任命为首席运营官。在加入本公司之前，Mills先生于1996年至2001年在Watson Pharmaceuticals，Inc.担任五年制造业务高级副总裁。在他制药生涯的34年间，1993至1996年他还担任Alpharma, Inc.的运营副总裁，并在Aventis SA担任过各种职务，包括工厂运营的总监。Mills先生拥有Grove City College的学士学位。
Robert S. Mills,has served as a member of Tff Pharmaceuticals, Inc. Board since January 2018. Mr. Mills also served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer from January 2018 to May 1, 2018, and also served as the Executive Chairman of Tff Pharmaceuticals, Inc. Board from January 2018 to December 2018. Mr. Mills has served as the founder and President of RSM Consulting, LLC since January 1, 2015. From August 2011 to December 2014, Mr. Mills was President and Chief Executive Officer of SPL Pharmaceuticals, the leading manufacturer of heparin and pancreatin, until its sale to a Chinese pharmaceutical company. Mr. Mills also served as a member of the board of directors of SPL Pharmaceuticals from 2011 to 2014. From May 2010 to February 2011, Mr. Mills served as President and as a member of the board of directors of Qualitest Pharmaceuticals, which was acquired by Endo Pharmaceuticals for $1.2 billion. From 2006 to 2010, Mr. Mills served as President and Chief Operating/Executive Officer and as a member of the board of directors of Columbia Laboratories, Inc., which has since been renamed Juniper Pharmaceuticals, Inc. (Nasdaq: CBRX). Mr. Mills has also served as a member of the board of directors of American Clinical Research Holdings since August 2022. Mr. Mills was recognized as a finalist for Entrepreneur of the Year for New Jersey in 2009 by Ernst and Young. Mr. Mills holds a B.S. Degree from Grove City College and numerous graduate business credits from Temple University. - Robert S. Mills曾担任总裁，自2006年1月起担任公司董事会成员。他于2006年3月至2009年12月担任首席执行官。Mills先生于2001年5月加入 Columbia，担任公司运营的高级副总裁，并于2003年9月被任命为首席运营官。在加入本公司之前，Mills先生于1996年至2001年在Watson Pharmaceuticals，Inc.担任五年制造业务高级副总裁。在他制药生涯的34年间，1993至1996年他还担任Alpharma, Inc.的运营副总裁，并在Aventis SA担任过各种职务，包括工厂运营的总监。Mills先生拥有Grove City College的学士学位。
- Robert S. Mills,has served as a member of Tff Pharmaceuticals, Inc. Board since January 2018. Mr. Mills also served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer from January 2018 to May 1, 2018, and also served as the Executive Chairman of Tff Pharmaceuticals, Inc. Board from January 2018 to December 2018. Mr. Mills has served as the founder and President of RSM Consulting, LLC since January 1, 2015. From August 2011 to December 2014, Mr. Mills was President and Chief Executive Officer of SPL Pharmaceuticals, the leading manufacturer of heparin and pancreatin, until its sale to a Chinese pharmaceutical company. Mr. Mills also served as a member of the board of directors of SPL Pharmaceuticals from 2011 to 2014. From May 2010 to February 2011, Mr. Mills served as President and as a member of the board of directors of Qualitest Pharmaceuticals, which was acquired by Endo Pharmaceuticals for $1.2 billion. From 2006 to 2010, Mr. Mills served as President and Chief Operating/Executive Officer and as a member of the board of directors of Columbia Laboratories, Inc., which has since been renamed Juniper Pharmaceuticals, Inc. (Nasdaq: CBRX). Mr. Mills has also served as a member of the board of directors of American Clinical Research Holdings since August 2022. Mr. Mills was recognized as a finalist for Entrepreneur of the Year for New Jersey in 2009 by Ernst and Young. Mr. Mills holds a B.S. Degree from Grove City College and numerous graduate business credits from Temple University.
高管简历
中英对照 | 中文 | 英文- Kirk Coleman
Kirk Coleman自2018年1月起担任我们的首席财务官。2012年以来，Coleman先生还担任Steelhead Capital Management，LLC和BIOS Partners，LP的执行官，这是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。从1998年到2008年，Coleman先生担任EFO Holdings，LP的财务主管，这是一家家族办公室。Coleman先生在风险资本投资方面有着超过20年的经验。Coleman先生于1995年在德克萨斯基督教大学（Texas Christian University）获得会计学学士学位。
Kirk Coleman,has served as Tff Pharmaceuticals, Inc. Chief Financial Officer since January 2018. Since 2012, Mr. Coleman also served as an executive officer of Steelhead Capital Management, LLC and Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. From 1998 to 2008, Mr. Coleman was Treasurer for EFO Holdings, LP, a family office. Mr. Coleman has over 20 years of experience in venture capital investments. Mr. Coleman received a BBA in Accounting from Texas Christian University in 1995.- Kirk Coleman自2018年1月起担任我们的首席财务官。2012年以来，Coleman先生还担任Steelhead Capital Management，LLC和BIOS Partners，LP的执行官，这是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。从1998年到2008年，Coleman先生担任EFO Holdings，LP的财务主管，这是一家家族办公室。Coleman先生在风险资本投资方面有着超过20年的经验。Coleman先生于1995年在德克萨斯基督教大学（Texas Christian University）获得会计学学士学位。
- Kirk Coleman,has served as Tff Pharmaceuticals, Inc. Chief Financial Officer since January 2018. Since 2012, Mr. Coleman also served as an executive officer of Steelhead Capital Management, LLC and Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. From 1998 to 2008, Mr. Coleman was Treasurer for EFO Holdings, LP, a family office. Mr. Coleman has over 20 years of experience in venture capital investments. Mr. Coleman received a BBA in Accounting from Texas Christian University in 1995.
- Harlan Weisman
Harlan Weisman自2018年12月起担任董事会成员。自2020年1月以来，Weisman博士一直担任Flame Biosciences，Inc.（一家临床阶段公司，专注于炎症驱动的癌症和其他炎症条件的转化疗法的研究，开发和商业化）的董事长兼首席执行官。自2012年以来，Weisman博士还一直担任AND-ONE Consulting，LLC的董事总经理，该公司从事为医疗产品公司，投资公司以及政府和非政府梦百合组织提供建议的业务，以制定和实施推动梦百合产品和服务创新的战略。自2014年以来，Weisman博士还担任3DBio Therapeutics的董事会执行主席，该公司使用3D生物打印技术开发完全整合到身体中的整个组织植入物。从2016年2月至2019年，Weisman博士担任Mycrobiomics的联合创始人兼首席科学官，该公司开发咨询和教育材料，以帮助消费者了解微生物组并改善其健康和福祉。2012年12月至2013年12月，Weisman博士担任Coronado Biosciences（一家生物制药公司，为自身免疫性疾病和癌症开发新型免疫疗法）的董事长兼首席执行官。2012年至2019年，Weisman博士曾担任Controlrad，Inc（一家医疗设备公司，开发技术以减少透视过程中的辐射暴露）的董事会成员。Weisman博士还担任Caelum Biosciences，Inc.的董事会成员。自2012年以来，魏斯曼博士还一直担任CRG的高级顾问，CRG是一家投资管理公司，对梦百合公司进行结构性债务和股权投资。自2016年以来，Weisman博士一直担任以色列生物技术基金（Israel Biotech Fund）的风险顾问，该基金投资和开发位于以色列的临床阶段生物技术公司。从2010年到2016年，Weisman博士担任以患者为中心的结果研究所的董事会成员，该研究所由美国国会成立，是2010年《患者保护和负担得起的医疗法案》的一部分。Weisman博士从2006年到2012年担任强生公司医疗设备和诊断集团首席科技官，并担任强生全球研发理事会主席。Weisman从2004年到2006年担任J&J Pharmaceutical Research&Development公司集团主席。
Harlan Weisman,has served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer since December 4, 2022. Dr. Weisman has also served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Since 2012, Dr. Weisman has also been Managing Director of And-One Consulting, LLC, which is engaged in the business of advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Since 2014, Dr. Weisman has also served as Executive Chairman of the Board of 3DBio Therapeutics, a company Tff Pharmaceuticals, Inc. ing 3D bioprinting technology to develop whole tissue implants that fully integrate into body. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer, from January 2020 to January 2022. From February 2016 through 2019, Dr. Weisman served as co-founder and Chief Scientific Officer for Mycrobiomics, a company developing counseling and educational material to help consumers to understand the microbiome and improve their health and well-being. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Between 2012 and 2019, Dr. Weisman served on the Board of Directors of ControlRad, Inc, a medical device company developing technology to reduce radiation exposure during fluoroscopic procedures. Dr. Weisman also served on the Board of Directors of Caelum Biosciences, Inc from 2019 until its acquisition by AstraZeneca in 2021. Since 2012, Dr. Weisman has also been an Operating Partner at CRG, an investment management firm making structured debt and equity investments in healthcare companies. Since 2016, Dr. Weisman has been a venture advisor to the Israel Biotech Fund, which invests and develops clinical-stage biotechnology companies based in Israel. From 2010 to 2016, Dr. Weisman served on the Board of Governors of the Patient Centered Outcomes Research Institute, established by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. Dr. Weisman was the Chief Science and Technology Officer of the Johnson & Johnson Medical Devices and Diagnostics Group from 2006 to 2012 and served as Chairman of the J&J Worldwide R&D Council. Dr. Weisman was Company Group Chairman of J&J Pharmaceutical Research & Development from 2004 to 2006.- Harlan Weisman自2018年12月起担任董事会成员。自2020年1月以来，Weisman博士一直担任Flame Biosciences，Inc.（一家临床阶段公司，专注于炎症驱动的癌症和其他炎症条件的转化疗法的研究，开发和商业化）的董事长兼首席执行官。自2012年以来，Weisman博士还一直担任AND-ONE Consulting，LLC的董事总经理，该公司从事为医疗产品公司，投资公司以及政府和非政府梦百合组织提供建议的业务，以制定和实施推动梦百合产品和服务创新的战略。自2014年以来，Weisman博士还担任3DBio Therapeutics的董事会执行主席，该公司使用3D生物打印技术开发完全整合到身体中的整个组织植入物。从2016年2月至2019年，Weisman博士担任Mycrobiomics的联合创始人兼首席科学官，该公司开发咨询和教育材料，以帮助消费者了解微生物组并改善其健康和福祉。2012年12月至2013年12月，Weisman博士担任Coronado Biosciences（一家生物制药公司，为自身免疫性疾病和癌症开发新型免疫疗法）的董事长兼首席执行官。2012年至2019年，Weisman博士曾担任Controlrad，Inc（一家医疗设备公司，开发技术以减少透视过程中的辐射暴露）的董事会成员。Weisman博士还担任Caelum Biosciences，Inc.的董事会成员。自2012年以来，魏斯曼博士还一直担任CRG的高级顾问，CRG是一家投资管理公司，对梦百合公司进行结构性债务和股权投资。自2016年以来，Weisman博士一直担任以色列生物技术基金（Israel Biotech Fund）的风险顾问，该基金投资和开发位于以色列的临床阶段生物技术公司。从2010年到2016年，Weisman博士担任以患者为中心的结果研究所的董事会成员，该研究所由美国国会成立，是2010年《患者保护和负担得起的医疗法案》的一部分。Weisman博士从2006年到2012年担任强生公司医疗设备和诊断集团首席科技官，并担任强生全球研发理事会主席。Weisman从2004年到2006年担任J&J Pharmaceutical Research&Development公司集团主席。
- Harlan Weisman,has served as Tff Pharmaceuticals, Inc. President and Chief Executive Officer since December 4, 2022. Dr. Weisman has also served as a member of Tff Pharmaceuticals, Inc. Board since December 2018. Since 2012, Dr. Weisman has also been Managing Director of And-One Consulting, LLC, which is engaged in the business of advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. Since 2014, Dr. Weisman has also served as Executive Chairman of the Board of 3DBio Therapeutics, a company Tff Pharmaceuticals, Inc. ing 3D bioprinting technology to develop whole tissue implants that fully integrate into body. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer, from January 2020 to January 2022. From February 2016 through 2019, Dr. Weisman served as co-founder and Chief Scientific Officer for Mycrobiomics, a company developing counseling and educational material to help consumers to understand the microbiome and improve their health and well-being. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Between 2012 and 2019, Dr. Weisman served on the Board of Directors of ControlRad, Inc, a medical device company developing technology to reduce radiation exposure during fluoroscopic procedures. Dr. Weisman also served on the Board of Directors of Caelum Biosciences, Inc from 2019 until its acquisition by AstraZeneca in 2021. Since 2012, Dr. Weisman has also been an Operating Partner at CRG, an investment management firm making structured debt and equity investments in healthcare companies. Since 2016, Dr. Weisman has been a venture advisor to the Israel Biotech Fund, which invests and develops clinical-stage biotechnology companies based in Israel. From 2010 to 2016, Dr. Weisman served on the Board of Governors of the Patient Centered Outcomes Research Institute, established by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. Dr. Weisman was the Chief Science and Technology Officer of the Johnson & Johnson Medical Devices and Diagnostics Group from 2006 to 2012 and served as Chairman of the J&J Worldwide R&D Council. Dr. Weisman was Company Group Chairman of J&J Pharmaceutical Research & Development from 2004 to 2006.
- Christopher Cano
Christopher Cano自2020年9月24日起担任我们的首席运营官兼业务发展副总裁，此前自2018年12月1日起担任我们的业务发展总监。加入公司之前，Cano先生担任Aqua Pharmaceuticals，LLC的业务开发副总裁，这是一家Almirall公司。在Aqua Pharmaceuticals之前，Cano先生是Duchesnay USA，Inc.的业务开发主管，并在Noven Pharmaceuticals，Inc.（一家Hitsamitsu公司），Agile Therapeutics，Liberty Medical，Nucryst Pharmaceuticals和Barrier Therapeutics担任过许多其他业务开发职务。Cano先生自2011年1月起担任C2Strategic Solutions，LLC的创始人和管理合伙人，这是一家咨询公司，为生命科学公司提供业务开发和许可服务。卡诺先生拥有维拉诺瓦大学的金融学士学位和莱德大学的商业管理硕士学位。
Christopher Cano,has served Tff Pharmaceuticals, Inc. Chief Operating Officer and Vice President of Business Development since September 24, 2020, and previously served as Tff Pharmaceuticals, Inc. Director of Business Development since December 1, 2018. Prior to joining the Company, Mr. Cano served as the Vice President of Business Development at Aqua Pharmaceuticals, LLC, an Almirall company. Prior to Aqua Pharmaceuticals, Mr. Cano was the Head of Business Development at Duchesnay USA, Inc. and held a number of other business development roles at Noven Pharmaceuticals, Inc., a Hitsamitsu company, Agile Therapeutics, Liberty Medical, Nucryst Pharmaceuticals, and Barrier Therapeutics. Mr. Cano has served as the founder and Managing Partner of C2 Strategic Solutions, LLC, a consulting firm providing business development and licensing services to life science companies since January 2011. Mr. Cano holds a bachelor's degree in finance from Villanova University and a master's degree in business management from Rider University.- Christopher Cano自2020年9月24日起担任我们的首席运营官兼业务发展副总裁，此前自2018年12月1日起担任我们的业务发展总监。加入公司之前，Cano先生担任Aqua Pharmaceuticals，LLC的业务开发副总裁，这是一家Almirall公司。在Aqua Pharmaceuticals之前，Cano先生是Duchesnay USA，Inc.的业务开发主管，并在Noven Pharmaceuticals，Inc.（一家Hitsamitsu公司），Agile Therapeutics，Liberty Medical，Nucryst Pharmaceuticals和Barrier Therapeutics担任过许多其他业务开发职务。Cano先生自2011年1月起担任C2Strategic Solutions，LLC的创始人和管理合伙人，这是一家咨询公司，为生命科学公司提供业务开发和许可服务。卡诺先生拥有维拉诺瓦大学的金融学士学位和莱德大学的商业管理硕士学位。
- Christopher Cano,has served Tff Pharmaceuticals, Inc. Chief Operating Officer and Vice President of Business Development since September 24, 2020, and previously served as Tff Pharmaceuticals, Inc. Director of Business Development since December 1, 2018. Prior to joining the Company, Mr. Cano served as the Vice President of Business Development at Aqua Pharmaceuticals, LLC, an Almirall company. Prior to Aqua Pharmaceuticals, Mr. Cano was the Head of Business Development at Duchesnay USA, Inc. and held a number of other business development roles at Noven Pharmaceuticals, Inc., a Hitsamitsu company, Agile Therapeutics, Liberty Medical, Nucryst Pharmaceuticals, and Barrier Therapeutics. Mr. Cano has served as the founder and Managing Partner of C2 Strategic Solutions, LLC, a consulting firm providing business development and licensing services to life science companies since January 2011. Mr. Cano holds a bachelor's degree in finance from Villanova University and a master's degree in business management from Rider University.
- Zamaneh Mikhak
Zamaneh Mikhak，自2023年1月起担任TFF Pharmaceuticals, Inc.首席医疗官。Mikhak博士是一位获得过敏和免疫学认证的医师-科学家委员会，拥有超过23年的临床经验和18年的基础和转化研究经验。她的行业经验涵盖大型制药公司和小型生物技术公司，包括生物制剂以及在多个治疗领域治疗罕见和常见病的小分子药物。Mikhak博士最近担任Cogent Biosciences的高级副总裁兼临床开发主管，负责公司主要临床项目的临床开发职能。在加入Cogent之前，她曾担任波士顿制药公司临床开发副总裁，领导Avizakimab的策略和临床开发，并在大流行期间执行了系统性红斑狼疮的全球2期研究。在此之前，作为Kiniksa制药的高级总监，Mikhak博士在大约两年的时间里将Vixarelimab从临床前阶段推进到7个适应症的2期研究，并为成功的IPO创造了数据。在加入Kiniksa之前，她在赛诺菲 Genzyme担任早期项目的翻译医学主管，并领导了一个食物过敏项目。在获得行业经验之前，米哈克博士在临床实践中工作了20多年。从2006年至2014年，她在马萨诸塞州总医院行医，为患有各种特应性和免疫性疾病的患者提供护理。在波士顿儿童医院任职期间，她建立了健康联系哮喘教育计划，确定并治疗了大约300名高危哮喘患者。米哈克博士是哈佛医学院的助理教授，作为NIH资助的首席研究员进行基础和转化研究。她是众多知名科学出版物的第一作者。Mikhak博士是过敏和免疫学委员会认证的。她在波士顿儿童医院完成了过敏和免疫学奖学金，并在华盛顿特区的儿童国家医疗中心完成了儿科住院治疗。她在宾夕法尼亚大学医学院获得了医学博士学位，在波士顿大学以优异成绩获得了细胞生物学学士学位。
Zamaneh Mikhak,has served as Tff Pharmaceuticals, Inc. Chief Medical officer since January 2023. Dr. Mikhak is a physician-scientist Board Certified in Allergy and Immunology with over 23 years of clinical experience and 18 years of basic and translational research experience. Her industry experience spans across big pharma and small biotech, including biologics and small molecules in rare and common diseases in multiple therapeutic areas. Dr. Mikhak most recently served as Senior Vice President, Head of Clinical Development for Cogent Biosciences, where she oversaw the clinical development function across the company's major clinical programs. Prior to Cogent, she served as Vice President, Clinical Development at Boston Pharmaceuticals where she led the strategy and clinical development of Avizakimab and executed a global Phase 2 study in systemic lupus erythematosus during the pandemic. Previously, as Senior Director at Kiniksa Pharmaceuticals, Dr. Mikhak advanced Vixarelimab from the preclinical stage into Phase 2 studies in seven indications in approximately two years and generated data towards a successful IPO. Prior to joining Kiniksa, she served as Translation Medicine Lead for early-stage programs across the portfolio at Sanofi Genzyme and led a program in food allergy. Prior to her industry experience, Dr. Mikhak spent over 20 years in clinical practice. From 2006-2014, she practiced medicine at Massachusetts General Hospital, where she provided care to patients with a variety of atopic and immunologic diseases. During her tenure with Boston Children's Hospital, she established the Healthy Link Asthma Education Program that identified and treated approximately 300 patients with high-risk asthma. Dr. Mikhak was an Assistant Professor at Harvard Medical School and conducted basic and translational research as an NIH funded Principal Investigator. She is the lead author on numerous high-profile scientific publications. Dr. Mikhak is Board Certified in Allergy and Immunology. She completed her Fellowship in Allergy and Immunology at Boston Children's Hospital and completed her Residency in Pediatrics at Children's National Medical Center in Washington, D.C. She received her M.D. from the University of Pennsylvania School of Medicine and her B.A. in Biology with distinction in Cell Biology from Boston University.- Zamaneh Mikhak，自2023年1月起担任TFF Pharmaceuticals, Inc.首席医疗官。Mikhak博士是一位获得过敏和免疫学认证的医师-科学家委员会，拥有超过23年的临床经验和18年的基础和转化研究经验。她的行业经验涵盖大型制药公司和小型生物技术公司，包括生物制剂以及在多个治疗领域治疗罕见和常见病的小分子药物。Mikhak博士最近担任Cogent Biosciences的高级副总裁兼临床开发主管，负责公司主要临床项目的临床开发职能。在加入Cogent之前，她曾担任波士顿制药公司临床开发副总裁，领导Avizakimab的策略和临床开发，并在大流行期间执行了系统性红斑狼疮的全球2期研究。在此之前，作为Kiniksa制药的高级总监，Mikhak博士在大约两年的时间里将Vixarelimab从临床前阶段推进到7个适应症的2期研究，并为成功的IPO创造了数据。在加入Kiniksa之前，她在赛诺菲 Genzyme担任早期项目的翻译医学主管，并领导了一个食物过敏项目。在获得行业经验之前，米哈克博士在临床实践中工作了20多年。从2006年至2014年，她在马萨诸塞州总医院行医，为患有各种特应性和免疫性疾病的患者提供护理。在波士顿儿童医院任职期间，她建立了健康联系哮喘教育计划，确定并治疗了大约300名高危哮喘患者。米哈克博士是哈佛医学院的助理教授，作为NIH资助的首席研究员进行基础和转化研究。她是众多知名科学出版物的第一作者。Mikhak博士是过敏和免疫学委员会认证的。她在波士顿儿童医院完成了过敏和免疫学奖学金，并在华盛顿特区的儿童国家医疗中心完成了儿科住院治疗。她在宾夕法尼亚大学医学院获得了医学博士学位，在波士顿大学以优异成绩获得了细胞生物学学士学位。
- Zamaneh Mikhak,has served as Tff Pharmaceuticals, Inc. Chief Medical officer since January 2023. Dr. Mikhak is a physician-scientist Board Certified in Allergy and Immunology with over 23 years of clinical experience and 18 years of basic and translational research experience. Her industry experience spans across big pharma and small biotech, including biologics and small molecules in rare and common diseases in multiple therapeutic areas. Dr. Mikhak most recently served as Senior Vice President, Head of Clinical Development for Cogent Biosciences, where she oversaw the clinical development function across the company's major clinical programs. Prior to Cogent, she served as Vice President, Clinical Development at Boston Pharmaceuticals where she led the strategy and clinical development of Avizakimab and executed a global Phase 2 study in systemic lupus erythematosus during the pandemic. Previously, as Senior Director at Kiniksa Pharmaceuticals, Dr. Mikhak advanced Vixarelimab from the preclinical stage into Phase 2 studies in seven indications in approximately two years and generated data towards a successful IPO. Prior to joining Kiniksa, she served as Translation Medicine Lead for early-stage programs across the portfolio at Sanofi Genzyme and led a program in food allergy. Prior to her industry experience, Dr. Mikhak spent over 20 years in clinical practice. From 2006-2014, she practiced medicine at Massachusetts General Hospital, where she provided care to patients with a variety of atopic and immunologic diseases. During her tenure with Boston Children's Hospital, she established the Healthy Link Asthma Education Program that identified and treated approximately 300 patients with high-risk asthma. Dr. Mikhak was an Assistant Professor at Harvard Medical School and conducted basic and translational research as an NIH funded Principal Investigator. She is the lead author on numerous high-profile scientific publications. Dr. Mikhak is Board Certified in Allergy and Immunology. She completed her Fellowship in Allergy and Immunology at Boston Children's Hospital and completed her Residency in Pediatrics at Children's National Medical Center in Washington, D.C. She received her M.D. from the University of Pennsylvania School of Medicine and her B.A. in Biology with distinction in Cell Biology from Boston University.